Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
Intern Med J
; 54(6): 1017-1030, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38881453
ABSTRACT
Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Linfoma de Células B de la Zona Marginal
Límite:
Humans
País/Región como asunto:
Oceania
Idioma:
En
Revista:
Intern Med J
/
Intern. med. j
/
Internal medicine journal
Asunto de la revista:
MEDICINA INTERNA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Australia